Latest News

Search News
Categories
Archives
Prof Nick Lemoine interviewed on Channel 4 News about long COVID

29th November 2021

During the interview, Professor Lemoine highlighted that studies being undertaken across the country aim to elucidate the mechanisms involved in long COVID, and further studies are being set up to identify treatments that will be effective against the disease.

Read more

International collaboration set to investigate new treatment strategy for lymphoma

24th November 2021

An international collaboration involving researchers from Queen Mary University of London, Memorial Sloan Kettering Cancer Center, New York and Dana-Farber Cancer Institute, Boston has secured a €1M research grant from Dutch blood cancer charity, Lymph&Co, to investigate a new treatment target for lymphoma.

Read more

Our Pancreatic Cancer Research: From BCI Bench to Bedside

18th November 2021

Pancreatic cancer is a core area of research focus at the Barts Cancer Institute, Queen Mary University of London, with a major aim being direct translation of laboratory research into clinical trials with the hope of improving outcomes for patients. Find out more this World Pancreatic Cancer Day.

Read more

Blood test predicts chemotherapy resistance in prostate cancer

11th November 2021

Research conducted at Barts Cancer Institute (BCI), Queen Mary University of London, indicates that regular blood tests before and during chemotherapy for prostate cancer can detect whether or not a patient is resistant or developing resistance to treatment with a drug called docetaxel. Ms Caitlin Davies, a PhD student at BCI, presented the findings from her PhD research at the National Cancer Research Institute (NCRI) Festival, which is taking place from 8-12th November 2021.

Read more

AI algorithm identifies most effective drugs for liver cancer

1st November 2021

Researchers from Barts Cancer Institute at Queen Mary University of London and King’s College Hospital have shown that a new computer-based algorithm can rank drugs used to treat primary liver cancer, based on their efficacy in reducing cancer cell growth.

Read more

Overcoming drug resistance in breast cancer

28th October 2021

In recognition of Breast Cancer Awareness Month, we spoke with Dr Ioanna Keklikoglou, Lecturer and Group Leader in the Centre for Tumour Microenvironment at Barts Cancer Institute, Queen Mary University of London. Dr Keklikoglou’s research focuses on understanding the molecular and cellular mechanisms that control resistance to anti-cancer therapies in breast cancer.

Read more

Search News
Categories
Archives
© 2013 ~ 2022 Cancer Research UK Barts Centre